Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $0.00 | $53.9M | $67.5M |
| Revenue growth | — | — | — | — | — | — | — | — | — | 25.2% |
| Operating income | — | — | — | — | — | — | -$140M | -$166M | -$193M | -$304M |
| Operating margin | — | — | — | — | — | — | — | — | -358.5% | -449.9% |
| Net income | -$27.6M | -$35.4M | -$60.4M | -$63.1M | -$89.6M | -$130M | -$136M | -$153M | -$174M | -$279M |
| Net margin | — | — | — | — | — | — | — | — | -322.9% | -412.9% |
| EPS (diluted) | -$1.47 | -$1.52 | -$1.72 | -$1.51 | -$1.69 | -$1.97 | -$2.03 | -$2.08 | -$2.02 | -$3.18 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25.3M | -$28.4M | -$48.7M | -$54.8M | -$69.8M | -$105M | -$110M | -$125M | $134M | -$64.1M |
| Capital expenditures | — | — | — | — | $2.17M | $1.15M | $626K | $168K | $472K | $6.64M |
| Free cash flow | — | — | — | — | -$72.0M | -$106M | -$111M | -$125M | $134M | -$70.7M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $9.72M | $11.4M | $16.1M | $26.1M | $325M | $90.7M | $51.8M | $37.3M | $224M | $149M |
| Total assets | $69.8M | $95.9M | $182M | $242M | $647M | $534M | $456M | $449M | $760M | $738M |
| Total liabilities | $12.9M | $16.0M | $21.4M | $23.2M | $36.3M | $27.4M | $36.0M | $51.7M | $347M | $564M |
| Long-term debt | $7.32M | $5.57M | $7.50M | $7.25M | $4.25M | — | $9.16M | $9.33M | $6.92M | $9.71M |
| Shareholders' equity | $56.9M | $79.9M | $161M | $219M | $611M | $507M | $420M | $397M | $414M | $174M |
| Retained earnings | -$53.9M | -$89.3M | -$150M | -$213M | -$303M | -$433M | -$569M | -$721M | -$895M | -$1.17B |
| Shares (wtd avg diluted) | 19.3M | 29.4M | 38.1M | 45.4M | 53.1M | 66.4M | 67.0M | 73.2M | 86.2M | 87.7M |
Every figure is extracted from Kura Oncology, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.